G enomic and epigenetic changes drive tumorigenesis through oncogene activation and loss of tumor suppressor genes (TSGs). Such alterations have been cataloged for a variety of cancers in studies of copy number, methylation, and mutational profiling; however, distinguishing causative from benign changes remains challenging (1, 2) . Although copy number alteration studies have discovered candidate oncogenes by examining large numbers of tumors for recurrent amplifications, putative TSG identification has proven more elusive for several reasons. First, TSGs are inactivated by multiple mechanisms, such as deletion, gene silencing, and mutation, resulting in low frequencies of inactivation by any one mechanism. High-frequency loss-of-function mutation of a given TSG (>10% incidence) is rare, suggesting that TSG pathways are inactivated in multiple ways (3) . Additionally, the intended target(s) of deletion regions often are difficult to identify because the regions are large and encompass many genes. Finally, loss of a single allele of a TSG may contribute to tumorigenesis through haploinsufficiency, further complicating TSG discovery (4) (5) (6) .
Many key negative regulators of proliferation also are potent TSGs. For example, mutations in the cell-cycle and apoptotic regulator TP53 that impair the cell's ability to growth arrest, undergo apoptosis, and efficiently repair damaged DNA are found in more than half of all cancers, (7) . Also, regulation of the G1/S transition is a common feature of many TSGs, such as the classical TSG, retinoblastoma 1 (RB1) (8) . Rb is directly phosphorylated and inactivated by cyclin D, as are its cognate cyclin-dependent kinase partners Cdk4 and Cdk6. Forced cyclin D overexpression in transgenic animals also drives tumorigenesis, and its overproduction is a common feature of human cancers (9) . Likewise, the most frequently deleted TSG region in humans is the CDKN2a-CDKN2b locus encoding p16 INK4a , p15 INK4b , and p14 ARF , the first two of which are inhibitors of Cdk4 and Cdk6 (10) . Loss of these genes results in hyperactivation of cyclin DCdk4/6 complexes and Rb inactivation. The frequency with which the p53 and Rb TSG pathways are inactivated in cancer underscores the importance of restraining proliferation and survival for tumor suppression.
Genetic screening is a robust method to identify loss-of-function phenotypes and can complement genomic efforts to distinguish TSGs from passenger alterations (11) . To perform loss-of-function screens, we developed bar-coded shRNA libraries that target the entire human genome and methods for large-scale, pooled RNAi screens (12) (13) (14) . We previously used these tools to identify suppressors of tumorigenesis and/or proliferation (STOP) genes, whose loss of function enhances normal cell proliferation and possibly cancer development (15) . This gene set is highly enriched for known TSGs as well as for genes deleted and mutant in cancers and likely contains many uncharacterized TSGs. STOP genes are highly enriched in regions of recurrent hemizygous deletions, whereas their counterpart genes, the GO genes, which represent essential functions, are underrepresented in these regions. Thus the Cancer Gene Island model proposes that tumors benefit from these recurrent focal deletions because the deletions impart a proliferative advantage to the tumor through cumulative haploinsufficiency. However, many STOP genes do not reside in regions of recurrent deletions but very well might contribute to tumorigenesis when mutant or silenced.
In this study, we have uncovered a tumor-suppressive role for one STOP gene, phosphatase and actin regulator 4 (PHACTR4). The proteins of the Phactr family interact with the serine-threonine phosphatase PP1 via their C termini and are characterized by the presence of several G-actin-binding RPEL domains (16, 17) . Although the function of these proteins remains unclear, Phactr proteins have been proposed to act as PP1 regulatory subunits responsible for substrate targeting. Here, we show that PHACTR4 acts as a TSG to restrain cell proliferation and transformation and is inactivated in several types of cancers.
Significance
Cell proliferation control is central to tumor suppression. We previously identified hundreds of suppressors of tumorigenesis and/or proliferation (STOP) genes that restrain normal cell proliferation. Here we show that one such STOP gene, phosphatase and actin regulator 4 (PHACTR4), acts to prevent tumorigenesis. Phactr4 suppresses proliferation and transformation in vitro and tumorigenesis in vivo. PHACTR4 is significantly mutated or downregulated in several cancers, and reintroduction of Phactr4 limits proliferation and tumor growth in cells from these cancers. Thus, our studies provide strong evidence that PHACTR4 is a tumor suppressor.
Results
Phactr4 Is a Candidate Tumor Suppressor. Cancer progression depends on the cell's ability to proliferate. Thus, we reasoned that proliferation might be a particularly good phenotype to interrogate genetically to identify TSGs. We previously performed RNAi screens to identify and validate STOP genes whose loss of function enhanced normal, hTERT-immortalized human mammary epithelial cell (HMEC) proliferation (15) . To determine bona fide TSGs in the STOP gene set, candidates that had not been implicated in tumorigenesis previously were prioritized as to whether they were significantly deleted or mutant in human cancers using databases of copy number analysis (Tumorscape) and sequencing (COSMIC) across cancers (18, 19) . PHACTR4, which encodes a 712-aa member of the Phactr family, emerged as a good candidate for further examination. Eight of 13 independent shRNAs targeting Phactr4 increased cell proliferation by twofold or more in our validation screen, and five of these shRNAs were enriched by more than fourfold (Fig. 1A) . Analysis of copy number data from >3,000 tumors revealed that PHACTR4 is located in a peak region of deletion in 6 of 14 subtypes of cancer examined ( Fig. 1 B and C) (18) . Located on the short arm of chromosome 1, PHACTR4 was deleted significantly in breast (35.8%, q = 3.5 × 10 ) [specifically in nonsmall cell lung (19.8%, q = 4.4 × 10 −5 )], neural (14.8%, q = 0.02), ovarian (24.3%,, q = 0.03), and renal (22.2%,, q = 1.2 × 10 −3 ) cancers but never was amplified significantly (Fig. 1C ). For reference, only 2.6% of all genes are deleted as significantly as PHACTR4 in as many (six or more) subtypes of cancer (18) . Significant focal deletions of PHACTR4 also were observed in these six cancer subtypes: breast, 13.6%; colorectal, 11.8%; lung, 7.1%; neural, 5.1%; ovarian, 14.6%; and renal, 10.3% (Fig. 1C) . When we examined all regions of focal deletion that were smaller than 5 Mb, we found seven lung cancers with small focal deletions of PHACTR4 (Fig. 1D) . Alignment of these focal deletions revealed a minimal region of less than 700 Kb containing PHACTR4 and 13 other genes, suggesting that loss of PHACTR4 may be a deletion target in these cancers. Furthermore, examination of whole-genome and exome sequencing data from 2,451 solid tumors (breast, biliary tract, large intestine, lung, kidney, ovary, and skin cancers) revealed 11 somatic loss-of-function (frameshift or nonsense) and 16 missense mutations of PHACTR4 (Fig. 1E) . Interestingly, a frameshift mutation in the N terminus of the protein (S64fs*12) resulting in a truncation product of only 75 aa was found in six tumors. Five of these six mutations occur within a homopolymeric stretch of 10 A nucleotides. Additionally, a frameshift mutation in the central proline-rich region of the protein (P356fs*33) was found twice. Because the C terminus of Phactr4 is required to bind PP1, the 11 nonsense or frameshift mutations observed in these tumors likely abolish this interaction. To determine if the loss-offunction PHACTR4 mutations observed in cancers are functionally relevant, we examined nonsynonymous versus synonymous mutations of PHACTR4 found in this cancer-sequencing dataset. If PHACTR4 inactivation was functionally relevant to tumorigenesis, one would expect the ratio of nonsynonymous-to-synonymous mutations would be higher than that observed across the entire genome. In fact, the nonsynonymous-to-synonymous mutation ratio for PHACTR4, 0.964 (P = 0.00583), was significantly higher than the average observed for all genes, 0.768, suggesting that nonsynonymous PHACTR4 mutations may contribute to tumorigenesis. Taken together, these data suggest that loss of Phactr4 function by either deletion or mutation may play a role in driving tumorigenesis. in cancers, and multiple Phactr4 shRNAs strongly increased proliferation in our screens, we wanted to examine whether this gene possesses TSG properties. To verify that Phactr4 can regulate the proliferation of HMECs, we sought to reproduce our findings from the validation screen using the two Phactr4 shRNAs (sh1 and, sh2) that demonstrated the most robust proliferation increases in the screen as well as an additional independent shRNA that was not screened (sh3). This third shRNA was designed using the DSIR algorithm. HMECs stably expressing shRNAs against Phactr4 or firefly luciferase (FF) were plated in triplicate, grown under normal growth conditions, and counted 4 d after plating. All three independent Phactr4 shRNAs significantly increased cell proliferation compared with FF (P = 0.007, 0.017, and 0.018 for sh1, sh2, and sh3, respectively) ( Fig. 2A) . In long-term growth assays, Phactr4 depletion reduced doubling time by 14% per generation and increased population doublings compared with FF negative controls (Fig. 2B) . Strikingly, Phactr4 depletion increased proliferation similar to the levels observed with a positive-control shRNA targeting p21, and the strongest depletion correlated with the most robust proliferation phenotype ( Fig. 2 B and C). Importantly, re-expression of an shRNA1-resistant Phactr4 at nearly endogenous levels significantly rescued the enhanced proliferation phenotype observed with Phactr4 sh1 (P = 0.007) but not Phactr4 sh2 ( Fig. 2 D and E). Furthermore, proliferation inversely correlated with Phactr4 protein levels (Fig. 2E ). These data indicate that the proliferation increases observed with Phactr4 shRNAs are not the result of off-target effects. Thus, Phactr4 is a regulator of cell proliferation and exhibits characteristics of a tumor suppressor. Previous work has suggested that Phactr4 plays a role in PP1 localization and Rb dephosphorylation (17) . Neural progenitor cells from mice defective for Phactr4 exhibit increased proliferation, inactive PP1, and Rb hyperphosphorylation. Thus, we reasoned that Phactr4 depletion in HMECs may increase cell proliferation through a similar mechanism. Consistent with these data, Phactr4 depletion maintains Rb phosphorylation following growth factor withdrawal (Fig. 2F ). These data suggest that Phactr4 loss increases cell proliferation, in part, through an abrogated G1 arrest.
Loss of TSGs such as p53 and Rb often confers tumor-like properties on cells. Anchorage-independent growth or transformation is one such property that is a common characteristic of cancer cells. To establish whether PHACTR4 loss can contribute to transformation, we used a colony-formation assay to measure anchorage-independent growth in HMECs expressing telomerase and large T antigen (TL-HMEC) (20, 21) . In these cells, Phactr4 depletion results in a dramatic increase in the number of anchorage-independent colonies compared with cells expressing an shRNA targeting FF (P = 8.9 × 10 −4 ) (Fig. 3 A and B) . Because these cells express large T antigen, which inhibits Rb, one would expect that Phactr4 depletion promotes anchorage-independent growth by an Rb-independent mechanism. Consistent with this idea, we found previously that Rb depletion does not promote transformation in this assay. These data indicate that Phactr4 acts similarly to known tumor suppressors to restrain cellular transformation and may contribute to tumorigenesis through multiple mechanisms.
Cancer Cells Are Hypersensitive to Phactr4 Complementation. Tumor cells bearing deletions of TSGs often display a property known as "tumor-suppressor hypersensitivity," in which re-expression of the lost TSG is deleterious to the growth and/or survival of the tumor cell (22, 23) (Fig. 3 C and D) . migrating bands were observed in multiple cell lines and are likely caused by alternatively spliced and/or modified versions of Phactr4. There are two Phactr4 transcripts which result in long (712 aa) and short (702 aa) isoforms. Furthermore, Phactr4 has been found to be acetylated and extensively phosphorylated in several large-scale phospho-proteomic analyses (24) . Importantly, these multiple bands disappear following Phactr4 depletion with shRNAs ( Fig. 2) . A renal carcinoma cell line, 769-P, which harbors a PHACTR4 deletion with a copy number of −0.82 (18), exhibits decreased Phactr4 expression compared with normal primary renal proximal tubule epithelial cells (Fig. 3C) . PHACTR4 likely is hemizygously deleted in 769-P cells, because low levels of Phactr4 protein can be observed. Furthermore, several breast cancer cell lines, including ZR-75-1, MCF-7, HCC1954, HCC2218, and BT474, show reduced Phactr4 expression compared with normal HMECs, primary BJ fibroblasts, or other breast cancer cell lines (HCC1143, HCC1937, HCC1395, and HCC38) (Fig. 3D ). HCC2218 cells likely have a hemizygous deletion of PHACTR4 (copy number = −0.64), but the remaining breast cancer cell lines have normal PHACTR4 copy number (18) . Complementation of 769-P cells and ZR-75-1 cells by constitutive Phactr4 re-expression at nearly endogenous levels significantly reduced proliferation by 34% (P = 0.007) and 47% (P = 3.8 × 10
), respectively, in shortterm growth experiments ( Fig. 3 E and F) . No effect of increased Phactr4 expression was observed in HCC1143 cells, which exhibit high endogenous Phactr4 expression. Thus, these cancer cell lines with reduced Phactr4 exhibit tumor-suppressor hypersensitivity following complementation, indicating that Phactr4 exhibits tumorsuppressive properties.
To determine if Phactr4 can act as a tumor suppressor in vivo, we developed a doxycycline (Dox)-inducible system for longterm expression of Phactr4 (Fig. 4A ). This two-plasmid inducible system, which we call "pInducer 3," links GFP expression to induction of a gene of interest through internal ribosome entry site (IRES)-mediated translation and allows GFP sorting of cells that exhibit robust and tight Dox-inducible expression. Using this system, Phactr4 induction significantly reduced 769-P proliferation in vitro by 59% compared with induction of the negative control, GAPDH (P = 0.004) (Fig. 4 B and C) . Furthermore, anchorageindependent growth of 769-P cells was reduced significantly, by 76%, following Phactr4 re-expression (P = 0.009) (Fig. 4D) . We next wished to determine the effect of Phactr4 complementation in vivo; however, 769-P cells do not form tumors in xenograft models. Thus, we used our Dox-inducible system to induce Phactr4 in two breast cancer cell lines (MCF-7 and ZR-75-1) which readily form tumors following s.c. injection into the flanks of nude mice (Fig. 4 E and F) . Phactr4 re-expression in these cells reduced breast cancer xenograft formation by 57% and 62%, respectively, suggesting that these cancer cell lines exhibit tumor-suppressor hypersensitivity in vivo. Collectively, these data indicate that Phactr4 is a tumor suppressor that is frequently deleted in several types of cancers.
Discussion
The STOP gene set we previously identified is significantly enriched for known tumor suppressors and likely contains many novel tumor suppressors. To identify bona fide tumor suppressors among the STOP genes, we combined genetic and genomic data to identify a candidate tumor suppressor, PHACTR4. PHACTR4 displays many classical properties of a tumor suppressor. First, it is deleted frequently in a wide range of cancers. Second, loss-of-function mutations are observed in several solid tumors. Third, it restrains proliferation, because eight shRNAs targeting Phactr4 in our validation screen were enriched for enhanced proliferation, and it restrains cellular transformation in an anchorage-independent growth assay. Furthermore, tumor lines lacking Phactr4 display hypersensitivity to Phactr4 reintroduction at wild-type levels. Finally, Phactr4 induction restrains the formation breast tumor xenografts, further demonstrating that Phactr4 has tumor-suppressive functions.
The Phactr family of proteins consists of four members, Phactr1-4, which are characterized by RPEL domains that mediate actin binding and the ability to bind the serine-threonine phosphatase, PP1, via their C termini (16) . Phactr proteins are thought to act as regulatory subunits responsible for targeting PP1 to various substrates. Such targeting subunits can mediate substrate selectivity by regulating the subcellular localization or activity of PP1 (25) . The founding family member, Phactr1, was identified through a yeast two-hybrid screen as a PP1α-interacting protein (16) . The other Phactr family members were identified by homology and subsequently were shown to coimmunoprecipitate with G-actin and PP1 (16, 17, 26) .
Because protein dephosphorylation is a primary mechanism for rapid down-regulation of proliferative signal transduction pathways, we reasoned that Phactr4 might play a tumor-suppressive role through PP1 regulation of proliferation. PP1 promotes efficient cell-cycle progression by dephosphorylating Rb in mitosis, allowing mitotic exit. Interestingly, mice identified in an N-ethyl-N-nitrosourea (ENU) mutagenesis screen that express a hypomorphic allele of Phactr4 (Phactr4 humdy/humdy ) are embryonic lethal at embryonic day (E) 10.5-14.5 and exhibit a failure to close the neural tube and optic fissure, exencephaly, and retinal coloboma. This mutation maps to a single missense mutation of R650P in the PP1-binding domain, disrupting the interaction of Phactr4 with PP1α, β, and γ. Increased proliferation, inactive PP1, and Rb hyperphosphorylation are all characteristics of neural progenitor cells in Phactr4 humdy/humdy mice. Consistent with a role regulating proliferation through PP1, we observed sustained Rb phosphorylation following growth factor withdrawal in Phactr4-depleted cells. The ability of Phactr4 to enhance proliferation likely is caused, in part, by its ability to restrain Rb activation. However, that function cannot explain all its suppressor activity, because loss of Phactr4 transforms HMECs expressing T antigen, in which the Rb pathway already is inactivated. Thus, Phactr4 is likely to regulate multiple functions that contribute to its tumor suppression activities.
One function of Phactr4 that could contribute to tumor suppression is its ability to bind G-actin. This interaction suggests that Phactr4 may regulate the actin cytoskeleton. Phactr4 has been shown previously to have a role in directional migration and cytoskeletal dynamics, because enteric neural crest cells from Phactr4 humdy/humdy mice show defects in cell migration and lamellipodia formation (27) . Consistent with a cytoskeletal role, we found that Phactr4 depletion promotes anchorage-independent growth. When cell-cell contact is prevented in soft agar growth assays, most cells undergo anoikis, a type of apoptosis that is triggered by the loss of integrin-matrix contact and actin cytoskeletal changes. Anchorage independence strongly correlates with transformation and invasion, suggesting that Phactr4 may play an additional tumor-suppressive role by promoting the cytoskeletal changes necessary to trigger cell death in the absence of cell-cell contact.
Tumor cell lines with reduced Phactr4 demonstrated hypersensitivity to Phactr4 complementation both in vitro and in mouse xenograft models. Future studies to investigate whether Phactr4 humdy/humdy mice are tumor prone should be particularly illuminating and may provide insight as to the pathways responsible for its tumor-suppressor function. Furthermore, most recurrent deletions of Phactr4 are hemizygous (i.e., only one copy is deleted), suggesting the possibility of haploinsufficiency. However, the mutation and methylation status of the second allele in these cancers have not been assessed. Furthermore, although some loss-of-function PHACTR4 mutations are found in cancers, inactivation of the second allele by silencing has not been examined in these cancers, either. Thus, further investigation is needed to determine whether Phactr4 acts in a haploinsufficient or recessive manner. Counts were normalized to GAPDH-expressing control cells grown without Dox and plotted. Statistical significance was determined using a Student t test. *P < 0.05. (D) Cancer cell line complementation with Phactr4 reduces anchorage-independent growth. 769-P cells from B were plated at equal densities in triplicate in 2% methylcellulose in the presence or absence of 200 ng/mL Dox. Cultures were fed weekly with 1 mL growth medium with or without 200 ng/mL Dox. Colonies were counted after 4 wk by counting 20 randomly selected fields per plate under 10× magnification. Counts were summed for each sample and normalized to uninduced controls. Statistical significance was determined using a Student t test. *P < 0.05. (E and F) Phactr4 induction reduces breast cancer xenograft formation in vivo. MCF-7 and ZR-75-cells were transduced with the pInducer 3 lentiviral system to express the reverse tet transactivator and Doxinducible Phactr4 or GAPDH. Cells were neomycin and puromycin selected, treated with 200 ng/mL Dox for 3 d, and FACS sorted for similar GFP expression. After sorting and cell line expansion in the absence of Dox, cells were injected s.c. into the flanks of nu/nu mice. Mice were fed ± Dox after tumors were established and were measured twice weekly.
In summary, the collection of STOP genes that restrain cell proliferation appears to be a rich source of tumor suppressors that could deeply inform efforts to annotate the cancer genome functionally. PHACTR4 is likely to be one of many potent tumor suppressors in the group of STOP genes that can be identified by combining our genetic analyses with genomic-alteration data. Importantly, because Phactr4 directs a phosphatase, it is likely that one or more phosphorylation events on key oncogenic pathways controlled by kinases are affected. If the kinases responsible for the relevant phosphorylation events could be identified, inhibitors to those kinases could be used to treat patients with tumors that lack PHACTR4. This situation is analogous to the one we previously reported with mutations in the protein tyrosine phosphatase PTPN12 (28) . Phospho-proteomic analysis of cells lacking PTPN12 identified a number of kinases that became hyperactive. Combinatorial inhibition with a pair of kinase inhibitors was able to inhibit the growth of tumors lacking PTPN12 in xenograft experiments. A similar situation could occur with Phactr4. Future experiments aimed at uncovering these relevant kinases opposed by Phactr4 should position us to develop therapies for Phactr4-driven cancers.
Materials and Methods
Cell Lines and Virus Production. HMECs from a reduction mammoplasty were purchased from Lonza, immortalized with human telomerase, and maintained in MEGM (Lonza). TL-HMECs were maintained as previously described (21) . 769-P, PRPTE, BJ, HCC1143, MCF-7, HCC1954, ZR-75-1, HCC1937, HCC2218, HCC1395, BT474, and HCC38 cells were purchased from the American Type Culture Collection and maintained as directed. MSCV-PM-shRNA retroviruses and pHAGE lentiviruses were produced as previously described (14, 29) . Viral supernatants were stored at −80°C before use.
Vectors and Cloning. Retroviral shRNAs were cloned into murine stem cell virus (MSCV)-PM as previously described (14) . pENTR223-Phactr4 was obtained from the ORFeome collection (30) and was sequence verified. pENTR223-Phactr4-STOP and pENTR223-Phactr4-Δ13-STOP (an shRNA1-resistant version of Phactr4 with 13 base-pair changes) were generated using QuikChange sitedirected mutagenesis (Invitrogen) and were used in subsequent LR reactions (Invitrogen) to recombine Phactr4 cDNA into Gateway-compatible MSCVGateway acceptor-Puro (MSCV-Phactr4-Puro) and MSCV-Gateway acceptorNeo (MSCV-Phactr4-Neo) vectors. The pInducer 3 system consists of two plasmids: pInducer 3 (pHAGE-TRE2-Gateway acceptor region-IRES-eGFP-PGKPuro) and prtTA3 (pHAGE-Ubc-rtTA3-IRES-Neo). pInducer 3 is a Gatewaycompatible entry vector, allowing a gene of interest to be cloned downstream of a Dox-inducible promoter (TRE2) and upstream of GFP to allow IRES-mediated translation of GFP linked to induction of a gene of interest. The second plasmid, prtTA3, provides neomycin-selectable, constitutive expression of a reverse tetracycline transactivator (rtTA3). This system allows GFP sorting of cells that exhibit Dox-inducible expression of a gene of interest. To generate pInducer 3, pInducer 21 (29) was cut with SmaI, and the 2.8-kb fragment was digested further with SphI/MfeI to generate a 1.4-kb SphI-SmaI fragment containing IRES-eGFP. This 1.4-kb fragment was cloned into an 8.5-kb fragment of pInducer 21 cut with BstB1, blunted with T4 DNA polymerase, and cut with SphI (containing the pHAGE backbone as well as the TRE3 and Gateway elements) to produce pML547. PGK-puro was PCR-amplified from MSCV-puro (Clontech) using the primers PGKf: CGGCATGGACGAGCTGTACAAGTAAAC-GCGTAATTCTACCGGGTAGGGGAG, PGKr: GGTAGCCAACGCTATGTCCTGAT-AGCCTGCAGGATCGATGCATGGGGTCGTGC and was inserted into the SphI/ RsrII sites of pML547 by SLIC (31) to generate pInducer 3 (pHAGE-TRE-Gateway acceptor region-IRES-GFP-PGK-Puro). To generate prtTA3, the TRE2 and Gateway elements were removed from pInducer 20 (29) by the following process: pInducer 20 was cut with PacI, blunted with T4 DNA polymerase, and cut with SphI, and the 3.3-kb fragment containing the Ubc promoter, rtTA3, and IRES-Neo was cloned into a 6.3-kb fragment of pInducer 20 cut with BamI, blunted with T4 DNA polymerase, cut with SphI, containing the pHAGE backbone. LR reactions containing pInducer 3 and pENTR223-Phactr4-STOP were used to produce pInducer 3-Phactr4. All cloning was performed with enzymes from New England BioLabs, QIAquick Gel Extraction kits from Qiagen, and DH5α bacteria from Invitrogen. The following shRNAs were used in this study: FF: TTAATCAGAGACTTCAGGCGGT; p21 sh1: TTCCTCTTGGAGA-AGATCAGCC; Phactr4 sh1: TTGATAACAATGTACCACTGTT; Phactr4 sh2: TTCTTTAA-CATGGCATCGCTTG; and Phactr4 sh3: CTTACTGGCTCTTCCTCTACTT.
Antibodies. The following antibodies were used for immunoblotting: rabbit anti-Phactr4 (HPA028985; Sigma), rabbit anti-tubulin (sc-9104; Santa Cruz), rabbit anti-GAPDH (sc-25778; Santa Cruz), mouse anti-actin (MAB1501; Millipore), mouse anti-Rb (554136; BD), mouse anti-vinculin (hVIN-1; Sigma), goat anti-rabbit-HRP (Jackson ImmunoResearch), and goat anti-mouse-HRP (Jackson ImmunoResearch).
Proliferation Assays. Proliferation experiments on HMECs and on 769-P, HCC1143, and ZR-75-1 cells were performed by plating cells in triplicate and measuring the number of cells after 3-8 d in culture in the presence or absence of indicated growth factors or 200 ng/mL Dox (Sigma). Statistically significant increases in proliferation were determined using a Student t test with P < 0.05.
Transformation Assays. TLM-HMECs or 769-P cells were plated in 2% (wt/vol) methylcellulose (Sigma) at a density of 50,000-150,000 cells per 6-cm dish as previously described (21) . The total number of TLM-HMEC anchorageindependent colonies was counted after 2-3 wk. 769-P anchorage-independent colonies were plated in the presence or absence of Dox and were fed weekly with medium with or without 200 ng/mL Dox. Colonies were assessed after 4 wk in culture by counting 20 randomly selected fields under the microscope and summing these fields for each triplicate. Triplicates were averaged for each sample and normalized to negative controls without Dox. Statistical significance was determined using a Student t test with P < 0.05.
Phactr4
Rescue Experiments. HMECs were transduced first with MSCV-PM shRNA retrovirus (FF, Phactr4 sh1, Phactr4 sh2) and selected for 4 d with 2 μg/mL puromycin. After selection, cells were transduced with retrovirus expressing an shRNA 1-resistant Phactr4 cDNA (MSCV-Phactr4-Δ13-STOP) or empty vector and were selected for an additional 7 d with 200 μg/mL neomycin (Invitrogen) and puromycin. Cells then were plated for proliferation assays at a density of 250,000 cells per 10-cm plate in triplicate in the presence of antibiotics. Cells were counted after 3 d and lysed for immunoblotting. Statistical significance was determined using a Student t test with P < 0.05. mice were randomized to the treatment and control groups, and mice in the treatment group (+Dox) were switched to food containing Dox. Mice were weighed and tumors were monitored twice weekly. Tumor volumes were calculated with the formula: volume (mm 3 ) = width × width × length × 0.5.
The significance was calculated by GraphPad Prism.
Deletion Analysis. Cancer deletion data were obtained from the Broad Institute's Tumorscape portal, www.broadinstitute.org/tumorscape (18) .
Mutation Analysis. To perform the analysis of PHACTR4 mutations, we used a dataset from whole-exome sequencing (in some cases whole-genome sequencing was performed) which was kindly provided by Simon Forbes at the Wellcome Trust Sanger Institute, Hinton, UK, and can be found at www.sanger. ac.uk/genetics/CGP (19) . In addition, four subsets of data from whole-exome sequencing derived from The Cancer Genome Atlas (TCGA) Data Portal (https:// tcga-data.nci.nih.gov/tcga) were used. substitution missense mutations, substitution nonsense mutations, frameshift deletions, and frameshift insertions (the number of nonsynonymous mutations was determined by subtracting the number of synonymous or silent mutations from the number of all mutations). To perform a statistical analysis of the ratio of PHACTR4 nonsynonymous versus synonymous mutations, we considered as a background level the average ratio of nonsynonymous mutations to the total number of mutations from the all datasets. Our estimate is consistent with previous reports, in which the ratio of nonsynonymous versus synonymous mutations was estimated to be 2.645 and 2.93 with two different methods (resulting in a ratio of nonsynonymous mutations to total mutations of 0.74) (32) . We then performed a one-tailed binomial test to determine whether the ratio of nonsynonymous mutations to the total number of mutations found in PHACTR4 was significantly higher than the background level in the all datasets (P = 0.00583).
